SEC Form S-8 POS filed by Calithera Biosciences Inc.

$CALA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CALA alert in real time by email
S-8 POS 1 d441086ds8pos.htm S-8 POS S-8 POS

As filed with the Securities and Exchange Commission on March 14, 2023

Registration No. 333-199126

Registration No. 333-204056

Registration No. 333-210193

Registration No. 333-216740

Registration No. 333-223533

Registration No. 333-230131

Registration No. 333-237089

Registration No. 333-254351

Registration No. 333-264044

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-199126

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-204056

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210193

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216740

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223533

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230131

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237089

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-254351

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-264044

UNDER THE SECURITIES ACT OF 1933

 

 

Calithera Biosciences, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   27-2366329

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

343 Oyster Point Blvd., Suite 200

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip code)

Calithera Biosciences, Inc. 2010 Equity Incentive Plan

Calithera Biosciences, Inc. 2014 Equity Incentive Plan

Calithera Biosciences, Inc. 2014 Employee Stock Purchase Plan

Calithera Biosciences, Inc. 2018 Inducement Plan

(Full title of the plans)

Susan M. Molineaux, Ph.D.

President and Chief Executive Officer

343 Oyster Point Blvd., Suite 200

South San Francisco, California 94080

(650) 870-1000

(Name, address of agent for service) (Telephone number, including area code, of agent for service)

Copies to:

John T. McKenna

Cooley LLP

3175 Hanover Street

Palo Alto, California 94304

(650) 843-5000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer  

   Smaller reporting company  

     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 


TERMINATION OF REGISTRATION

This post-effective amendment (the “Post-Effective Amendment”) relates to the following registration statements of Calithera Biosciences, Inc. (the “Company”) on Form S-8 (collectively, the “Registration Statements”):

 

 

Registration Statement on Form S-8 (File No. 333-199126), registering 118,492 shares of common stock of the Company, par value $0.0001 per share, filed with the Securities and Exchange Commission on October 2, 2014;

 

 

Registration Statement on Form S-8 (File No. 333-204056), registering 44,859 shares of common stock of the Company, par value $0.0001 per share, filed with the Securities and Exchange Commission on May 11, 2015;

 

 

Registration Statement on Form S-8 (File No. 333-210193), registering 45,580 shares of common stock of the Company, par value $0.0001 per share, filed with the Securities and Exchange Commission on March 15, 2016;

 

 

Registration Statement on Form S-8 (File No. 333-216740), registering 53,755 shares of common stock of the Company, par value $0.0001 per share, filed with the Securities and Exchange Commission on March 16, 2017;

 

 

Registration Statement on Form S-8 (File No. 333-223533), registering 134,019 shares of common stock of the Company, par value $0.0001 per share, filed with the Securities and Exchange Commission on March 8, 2018;

 

 

Registration Statement on Form S-8 (File No. 333-230131), registering 90,169 shares of common stock of the Company, par value $0.0001 per share , filed with the Securities and Exchange Commission on March 7, 2019;

 

 

Registration Statement on Form S-8 (File No. 333-237089), registering 139,529 shares of common stock of the Company, par value $0.0001 per share, filed with the Securities and Exchange Commission on March 11, 2020;

 

 

Registration Statement on Form S-8 (File No. 333-254351), registering 153,872 shares of common stock of the Company, par value $0.0001 per share, filed with the Securities and Exchange Commission on March 16, 2021; and

 

 

Registration Statement on Form S-8 (File No. 333-264044), registering 166,789 shares of common stock of the Company, par value $0.0001 per share, filed with the Securities and Exchange Commission on April 1, 2022.

On January 9, 2023, Calithera Biosciences, Inc. announced that our Board of Directors had unanimously approved the dissolution and liquidation of Calithera Biosciences, Inc. pursuant to a plan of complete liquidation and dissolution, subject to stockholder approval.

As a result of our planned dissolution, by filing this Post-Effective Amendment, the Company has terminated any and all offerings of its securities pursuant to the Registration Statements. Accordingly, the Company hereby terminates the effectiveness of each Registration Statement and removes from registration any and all securities of the Company registered but unsold under the Registration Statements as of the date hereof. All share numbers herein have been adjusted to reflect the one-for-twenty (1:20) reverse stock split of our outstanding common stock, effective as of June 14, 2022.


SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on March 14, 2023.

 

CALITHERA BIOSCIENCES, INC.
By:  

/S/ SUSAN M. MOLINEAUX, PH.D.

  Name:   Susan M. Molineaux, Ph.D.
  Title:   President and Chief Executive Officer

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

Get the next $CALA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CALA

DatePrice TargetRatingAnalyst
1/31/2022$4.00Buy
Ladenburg Thalmann
1/20/2022$1.00 → $3.00Market Perform → Outperform
SVB Leerink
11/8/2021Buy → Neutral
HC Wainwright & Co.
11/5/2021Outperform → Market Perform
William Blair
More analyst ratings

$CALA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

    SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: "CALA"). Calithera Biosciences, Inc. (the "Company") announced that it was unable to achieve a quorum of stockholders at its special meeting of stockholders scheduled to be held on June 29, 2023 (the "Special Meeting"), for the purpose of approving the Company's Plan of Complete Liquidation and Dissolution. In January 2023, the Company announced its intention to commence an orderly wind down of the Company's business and operations. After consulting with its proxy solicitation advisors, the Company concluded that further attempts to solicit proxies for the Special Meeting would in all likelihoo

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

    SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC:CALA) (the "Company") announced that it intends to hold a special meeting of stockholders on or about June 29, 2023 (the "Special Meeting"),  for the purpose of approving the Company's Plan of Complete Liquidation and Dissolution (the "Plan of Dissolution").  In January 2023, the Company announced its intention to commence an orderly wind down of the Company's business and operations.   The Company continues to expect that its existing capital resources together with the net proceeds from the sale of its assets will enable it to meet its remaining liabilities and obligations with sufficient reser

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

    SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company's operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinical development programs and reducing its workforce, including the termination of most employees by the end of the first quarter. "The Board of Directors and management devoted substantial t

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CALA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CALA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CALA
SEC Filings

See more

$CALA
Leadership Updates

Live Leadership Updates

See more
  • Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 50,000 shares of Calithera’s common stock, at a per share exercise price of $4.91, the closing trading price on December 31, 2020. One-fourth of the option vests in December 2021, and the balance of the option vests in a series of thirty-six successive equ

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CALA
Financials

Live finance-specific insights

See more
  • Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the third quarter ended September 30, 2022. "Earlier in the fourth quarter, we were very pleased to announce that we received FDA Fast Track designation for sapanisertib. This designation facilitates more frequent communication with the Agency, as well as a number of other benefits that could support our efforts to bring sapanisertib to patients in this area of high unmet need more quickly," said Susan Molineaux, PhD, president and chief executive officer of Calithera. "Today we a

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. Participants who wish to join the conference call by telephone can use this link to register and receive the dial-in numbers and unique PIN to access the call. The conference call registration and live audio webcast c

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022. "We continue to deliver on our commitment to efficiently advance our clinical programs, successfully initiating two new clinical trials and sharing program updates at two important medical conferences," said Susan Molineaux, PhD, president and chief executive officer of Calithera. "We look forward to sharing data from the ongoing mivavotinib and sapanisertib phase 2 trials by the first quarter of 2023, as well as providing an update on the p

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CALA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more